Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer : Results from the European Prospective Investigation into Cancer and Nutrition study
© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC..
Resistin is a protein involved in inflammation and angiogenesis processes and may play a role in the progression of colorectal cancer (CRC). However, it remains unclear whether resistin is associated with increased mortality after CRC diagnosis. We examined pre-diagnostic serum resistin concentrations in relation to CRC-specific and all-cause mortality among 1343 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. For CRC-specific mortality as the primary outcome, hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated from competing risk analyses based on cause-specific Cox proportional hazards models and further in sensitivity analyses using Fine-Gray proportional subdistribution hazards models. For all-cause mortality as the secondary outcome, Cox proportional hazards models were used. Subgroup analyses were performed by sex, tumor subsite, tumor stage, body mass index and time to CRC diagnosis. Resistin was measured on a median of 4.8 years before CRC diagnosis. During a median follow-up of 8.2 years, 474 deaths from CRC and 147 deaths from other causes were observed. Resistin concentrations were not associated with CRC-specific mortality (HRQ4vsQ1 = 0.95, 95% CI: 0.73-1.23; Ptrend = .97; and HRper doubling of resistin concentration = 1.00; 95% CI: 0.84-1.19; P = .98) or all-cause mortality. Results from competing risk (sensitivity) analysis were similar. No associations were found in any subgroup analyses. These findings suggest no association between pre-diagnostic circulating resistin concentrations and CRC-specific or all-cause mortality among persons with CRC, and the potential insignificance of resistin in CRC progression.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:154 |
---|---|
Enthalten in: |
International journal of cancer - 154(2024), 9 vom: 01. März, Seite 1596-1606 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pham, Thu Thi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Colorectal cancer |
---|
Anmerkungen: |
Date Completed 07.03.2024 Date Revised 07.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/ijc.34830 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36691281X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM36691281X | ||
003 | DE-627 | ||
005 | 20240307232203.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240114s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/ijc.34830 |2 doi | |
028 | 5 | 2 | |a pubmed24n1319.xml |
035 | |a (DE-627)NLM36691281X | ||
035 | |a (NLM)38200695 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pham, Thu Thi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer |b Results from the European Prospective Investigation into Cancer and Nutrition study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.03.2024 | ||
500 | |a Date Revised 07.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. | ||
520 | |a Resistin is a protein involved in inflammation and angiogenesis processes and may play a role in the progression of colorectal cancer (CRC). However, it remains unclear whether resistin is associated with increased mortality after CRC diagnosis. We examined pre-diagnostic serum resistin concentrations in relation to CRC-specific and all-cause mortality among 1343 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. For CRC-specific mortality as the primary outcome, hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated from competing risk analyses based on cause-specific Cox proportional hazards models and further in sensitivity analyses using Fine-Gray proportional subdistribution hazards models. For all-cause mortality as the secondary outcome, Cox proportional hazards models were used. Subgroup analyses were performed by sex, tumor subsite, tumor stage, body mass index and time to CRC diagnosis. Resistin was measured on a median of 4.8 years before CRC diagnosis. During a median follow-up of 8.2 years, 474 deaths from CRC and 147 deaths from other causes were observed. Resistin concentrations were not associated with CRC-specific mortality (HRQ4vsQ1 = 0.95, 95% CI: 0.73-1.23; Ptrend = .97; and HRper doubling of resistin concentration = 1.00; 95% CI: 0.84-1.19; P = .98) or all-cause mortality. Results from competing risk (sensitivity) analysis were similar. No associations were found in any subgroup analyses. These findings suggest no association between pre-diagnostic circulating resistin concentrations and CRC-specific or all-cause mortality among persons with CRC, and the potential insignificance of resistin in CRC progression | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a EPIC | |
650 | 4 | |a colorectal cancer | |
650 | 4 | |a mortality | |
650 | 4 | |a pre-diagnostic | |
650 | 4 | |a resistin | |
650 | 4 | |a survival | |
650 | 7 | |a Resistin |2 NLM | |
700 | 1 | |a Nimptsch, Katharina |e verfasserin |4 aut | |
700 | 1 | |a Aleksandrova, Krasimira |e verfasserin |4 aut | |
700 | 1 | |a Jenab, Mazda |e verfasserin |4 aut | |
700 | 1 | |a Fedirko, Veronika |e verfasserin |4 aut | |
700 | 1 | |a Wu, Kana |e verfasserin |4 aut | |
700 | 1 | |a Eriksen, Anne Kirstine |e verfasserin |4 aut | |
700 | 1 | |a Tjønneland, Anne |e verfasserin |4 aut | |
700 | 1 | |a Severi, Gianluca |e verfasserin |4 aut | |
700 | 1 | |a Rothwell, Joseph |e verfasserin |4 aut | |
700 | 1 | |a Kaaks, Rudolf |e verfasserin |4 aut | |
700 | 1 | |a Katzke, Verena |e verfasserin |4 aut | |
700 | 1 | |a Catalano, Alberto |e verfasserin |4 aut | |
700 | 1 | |a Agnoli, Claudia |e verfasserin |4 aut | |
700 | 1 | |a Masala, Giovanna |e verfasserin |4 aut | |
700 | 1 | |a De Magistris, Maria Santucci |e verfasserin |4 aut | |
700 | 1 | |a Tumino, Rosario |e verfasserin |4 aut | |
700 | 1 | |a Vermeulen, Roel |e verfasserin |4 aut | |
700 | 1 | |a Aizpurua, Amaia |e verfasserin |4 aut | |
700 | 1 | |a Trobajo-Sanmartín, Camino |e verfasserin |4 aut | |
700 | 1 | |a Chirlaque, María-Dolores |e verfasserin |4 aut | |
700 | 1 | |a Sánchez, Maria-Jose |e verfasserin |4 aut | |
700 | 1 | |a Lu, Sai San Moon |e verfasserin |4 aut | |
700 | 1 | |a Cross, Amanda J |e verfasserin |4 aut | |
700 | 1 | |a Christakoudi, Sofia |e verfasserin |4 aut | |
700 | 1 | |a Weiderpass, Elisabete |e verfasserin |4 aut | |
700 | 1 | |a Pischon, Tobias |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 154(2024), 9 vom: 01. März, Seite 1596-1606 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
773 | 1 | 8 | |g volume:154 |g year:2024 |g number:9 |g day:01 |g month:03 |g pages:1596-1606 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.34830 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 154 |j 2024 |e 9 |b 01 |c 03 |h 1596-1606 |